Weight-Loss drugs may have secret heart benefits – new study investigates
NCT ID NCT07483801
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This pilot study looks at how the diabetes and weight-loss drugs semaglutide and tirzepatide directly affect blood vessels and heart function, beyond their known effects on weight. Researchers will infuse the drugs into the arm or bloodstream of 112 volunteers with different body weights and blood pressures. The goal is to understand why these drugs lower blood pressure, which could lead to better treatments for heart disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
semaglutide and tirzepatide
What this could lead to
If it works, this could help explain how these drugs lower blood pressure beyond just weight loss, potentially leading to better heart treatments.
What could go wrong
This is a small, early pilot study (Phase 4) with only 112 participants, so results may not apply to everyone. It is designed to gather information, not to prove a treatment works.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Addenbrooke's Hospital
Cambridge, Cambridgeshire, CB20QQ, United Kingdom
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact